{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:36:05Z","timestamp":1792708565081,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.neulet.2021.136399","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T01:52:11Z","timestamp":1639619531000},"page":"136399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Association of plasma \u03b1-synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson\u2019s disease"],"prefix":"10.1016","volume":"770","author":[{"given":"Don Gueu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Sil","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaerak","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Han","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neulet.2021.136399_b0005","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-018-4183-0","article-title":"Myocardial MIBG scintigraphy in genetic Parkinson\u2019s disease as a model for Lewy body disorders","volume":"46","author":"Gabilondo","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.neulet.2021.136399_b0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.parkreldis.2009.12.010","article-title":"Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease","volume":"16","author":"Kashihara","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.neulet.2021.136399_b0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02984560","article-title":"Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease","volume":"18","author":"Taki","year":"2004","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.neulet.2021.136399_b0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.arr.2016.01.001","article-title":"(123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in alpha-synucleinopathies","volume":"30","author":"Orimo","year":"2016","journal-title":"Ageing research reviews"},{"issue":"1-2","key":"10.1016\/j.neulet.2021.136399_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jns.2005.08.011","article-title":"Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease","volume":"240","author":"Suzuki","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neulet.2021.136399_b0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14802\/jmd.15015","article-title":"123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review","volume":"8","author":"Chung","year":"2015","journal-title":"JMD"},{"key":"10.1016\/j.neulet.2021.136399_b0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jns.2017.09.010","article-title":"Cardiac sympathetic denervation and dementia in de novo Parkinson's disease: A 7-year follow-up study","volume":"381","author":"Choi","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"2006","key":"10.1016\/j.neulet.2021.136399_b0040","first-page":"1435","article-title":"The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy, Journal of neural transmission (Vienna","volume":"113","author":"Lee","year":"1996","journal-title":"Austria"},{"key":"10.1016\/j.neulet.2021.136399_b0045","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma alpha-synuclein predicts cognitive decline in Parkinson's disease","volume":"88","author":"Lin","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neulet.2021.136399_b0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma alpha-synuclein is decreased in subjects with Parkinson's disease","volume":"204","author":"Li","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2021.136399_b0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.22928","article-title":"Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2021.136399_b0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pjnns.2017.11.009","article-title":"The relation between plasma alpha-synuclein level and clinical symptoms or signs of Parkinson's disease","volume":"52","author":"Malec-Litwinowicz","year":"2018","journal-title":"Neurol. Neurochir. Pol."},{"issue":"1","key":"10.1016\/j.neulet.2021.136399_b0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","article-title":"Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease","volume":"480","author":"Shi","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2021.136399_b0070","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"issue":"2017","key":"10.1016\/j.neulet.2021.136399_b0075","first-page":"353","article-title":"Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease, Journal of neural transmission (Vienna","volume":"124","author":"Ding","year":"1996","journal-title":"Austria"},{"issue":"4","key":"10.1016\/j.neulet.2021.136399_b0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson's disease","volume":"7","author":"Park","year":"2011","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.neulet.2021.136399_b0085","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neulet.2021.136399_b0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.neulet.2021.136399_b0095","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/acn3.729","article-title":"Plasma alpha-synuclein detected by single molecule array is increased in PD","volume":"6","author":"Ng","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.neulet.2021.136399_b0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.neulet.2021.136399_b0105","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00702-021-02423-y","article-title":"Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson's disease","volume":"128","author":"Park","year":"2021","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.neulet.2021.136399_b0110","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00415-014-7560-z","article-title":"Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease","volume":"262","author":"Compta","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.neulet.2021.136399_b0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2020.10.016","article-title":"Comparison of 123I-MIBG scintigraphy and phosphorylated \u03b1-synuclein skin deposits in synucleinopathies","volume":"81","author":"Giannoccaro","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neulet.2021.136399_b0120","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1038\/s41598-019-42399-0","article-title":"Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid","volume":"9","author":"Kakuda","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neulet.2021.136399_b0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.parkreldis.2020.07.004","article-title":"Negative alpha-synuclein pathology in the submandibular gland of patients carrying PRKN pathogenic variants","volume":"81","author":"Shin","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neulet.2021.136399_b0130","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid \u03b1-Synuclein in prodromal and early Parkinson's disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2021.136399_b0135","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","article-title":"Systemic synuclein sampling, in vivo distribution of alpha-synuclein in multiple tissues and biofluids in Parkinson DISEASE","volume":"95","author":"Chahine","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2021.136399_b0140","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/brain\/awaa238","article-title":"Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study","volume":"143","author":"Horsager","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neulet.2021.136399_b0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2017.01.042","article-title":"Combined use of dopamine transporter imaging (DAT-SPECT) and (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease","volume":"375","author":"Yoshii","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.neulet.2021.136399_b0150","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12149-013-0702-z","article-title":"Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease","volume":"27","author":"Chiaravalloti","year":"2013","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.neulet.2021.136399_b0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.parkreldis.2019.02.012","article-title":"Striatal dopamine activity and myocardial (123)I-metaiodobenzylguanidine uptake in early Parkinson's disease","volume":"63","author":"Oh","year":"2019","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021007783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021007783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:40:50Z","timestamp":1759624850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394021007783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"alternative-id":["S0304394021007783"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136399","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of plasma \u03b1-synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"136399"}}